Tagged with B

Saudi Arabia Dr Abdulaziz Alswailem, the CEO of the Saudi Authority for Intellectual Property (SAIP), reflects on the country’s growing role in global intellectual property (IP) policy. He highlights Saudi Arabia’s efforts to foster a strong IP ecosystem through national and international collaborations, such as the Riyadh Design Law Treaty, which sets…

Saudi Arabia Dr. Helmut M. Schuehsler, CEO of TVM Capital Healthcare, shares insights into the firm’s investment strategy spanning the Middle East and Southeast Asia with a particular focus on Saudi Arabia’s rapidly evolving healthcare landscape. He discusses how TVM Capital Healthcare is driving transformation by scaling healthcare businesses, introducing innovative care…

Saudi Arabia Mohamed Fawzy, Country President for Pfizer Saudi Arabia, discusses the company’s evolving role in supporting the Kingdom’s rapidly transforming healthcare sector. He shares insights on Pfizer’s local footprint, its contributions to public health through innovative vaccines and oncology treatments, and the company’s commitment to talent development and localization. Fawzy also…

Global Since Paul Hudson took the helm in 2019, Sanofi has been in transformation mode, shedding its consumer health assets to focus on high-growth areas like oncology, immunology, and vaccines. With bold investments in R&D and AI-driven innovation, the French pharma is positioning itself as a pure-play biopharma leader. In conversation…

Japan Santen is on a mission to reshape the future of eye health. With three major product launches ahead, bold biotech deals, and a revamped global strategy, the Japanese pharma is doubling down on its ophthalmology dominance. Fresh off a transformational reorganization and a landmark myopia approval, Santen is proving that…

Saudi Arabia Baraya Extended Care is reshaping Saudi Arabia’s healthcare system, addressing critical gaps in long-term care and rehabilitation with bold innovation and a scalable vision. Backed by TVM Capital Healthcare Partners, it integrates advanced technologies and strategic partnerships to redefine specialized care while aligning with Vision 2030. As CEO Jad Halaby…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction of US biotech Illumina; Bio X Cell’s new Beijing distribution centre, and the European approval of Shanghai Henlius Biotech’s extensive-stage…

Europe European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan Eder is now at the forefront of driving the change that Europe needs. In this new role as head of…

Mexico Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example, often face delayed diagnoses, limited treatment options, and a lack of specialised care compared to those suffering from more common…

Mexico Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent according to a 2023 CANIFARMA and INEGI study. That makes it, on paper, appear a highly attractive sector for investment,…

Mexico In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms of prevalence, a full two-thirds of the adult Mexican population are nowadays classified as overweight or obese. “This is a…

Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…